Are you planning to attend AACR 2025 in Chicago, Illinois on April 27 – 30, 2025?

If so, make sure to connect with Abzena at the event! We will be exhibiting in booth #4850 and our Head of Bioassay, Dr Erika Kovacs, and Assoc. Director of Process Development for Conjugation, Austin McKinsey, will be on hand to learn more about your project-specific needs and update you our expanded capabilities that support oncology drug development.

Abzena is the leading bioconjugate & biologics CDMO+CRO, providing fully integrated, tailored drug design, development & GMP manufacturing services spanning from discovery through commercial for global biotech and pharma customers. Whether you need support with an ADC, AOC or RDC, our drug development experts can guide you towards a faster path to clinical and commercial success.

We are ready to discuss how we can help de-risk and streamline your program with innovative solutions like AbZelectPRO™ – high-yielding cell line development, or ThioBridge™ – site specific conjugation technology, that can improve your oncology program’s chances of success.

Schedule a meeting with our experts at AACR to learn how we can rapidly move your program forward to its next milestone – with greater success!